Poxel : New opportunities open up for Poxel
>Metavant exits diabetes - Poxel announced on the morning of Friday, 20 November that Metavant, a subsidiary of Roivant, its partner for the past 2 and a half years in the development of imeglimin in the USA and Europe, has decided to withdraw from the future phase III. This decision, motivated by strategic considerations specific to Roivant ("holding company which owns Metavant") which seems to want to withdraw from diabetes, does not in any way compromise, in our vi...Poxel is a clinical-stage biopharmaceutical company focused on the development of treatments for type 2 diabetes and metabolic disease. Co.'s two drug candidates, Imeglimin and PXL770, are intended to complement and augment existing type 2 diabetes therapies, including in patients who no longer fully respond to such therapies, with the goal of helping patients better control their type 2 diabetes and reduce potentially disabling or fatal complications.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.